ADAP

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Adaptimmune Therapeutics Plc

NASDAQ | ADAP

0.14

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 26, 2025)

$33.66M

Market Cap

-

P/E Ratio

-0.66

EPS

$1.00

52 Week High

$0.04

52 Week Low

HEALTHCARE

Sector

ADAP Chart

Recent Chart
Price Action

ADAP Technicals

Tags:

ADAP Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $178M
Total Revenue $178M
Cost Of Revenue $70K
Costof Goods And Services Sold $70K
Operating Income -$69M
Selling General And Administrative $81M
Research And Development $149M
Operating Expenses $247M
Investment Income Net -
Net Interest Income $3.2M
Interest Income $6.6M
Interest Expense $3.3M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $11M
Income Before Tax -$67M
Income Tax Expense $3.6M
Interest And Debt Expense -
Net Income From Continuing Operations -$71M
Comprehensive Income Net Of Tax -
Ebit -$64M
Ebitda -$53M
Net Income -$71M

Revenue & Profitability

Earnings Performance

ADAP Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $246M
Total Current Assets $188M
Cash And Cash Equivalents At Carrying Value $91M
Cash And Short Term Investments $91M
Inventory $7.3M
Current Net Receivables $16M
Total Non Current Assets $58M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $3.9M
Intangible Assets Excluding Goodwill $3.9M
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $60M
Other Current Assets $13M
Other Non Current Assets -
Total Liabilities $234M
Total Current Liabilities $65M
Current Accounts Payable $8.7M
Deferred Revenue -
Current Debt -
Short Term Debt $9.4M
Total Non Current Liabilities $170M
Capital Lease Obligations $24M
Long Term Debt $50M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $74M
Other Current Liabilities $34M
Other Non Current Liabilities $4.3M
Total Shareholder Equity $12M
Treasury Stock -
Retained Earnings -$1.1B
Common Stock $2.1M
Common Stock Shares Outstanding $252M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$73M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $11M
Capital Expenditures $2.7M
Change In Receivables -
Change In Inventory -$7.4M
Profit Loss -
Cashflow From Investment -$59M
Cashflow From Financing $79M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$71M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $178M
Total Revenue $178M
Cost Of Revenue $70K
Costof Goods And Services Sold $70K
Operating Income -$69M
Selling General And Administrative $81M
Research And Development $149M
Operating Expenses $247M
Investment Income Net -
Net Interest Income $3.2M
Interest Income $6.6M
Interest Expense $3.3M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $11M
Income Before Tax -$67M
Income Tax Expense $3.6M
Interest And Debt Expense -
Net Income From Continuing Operations -$71M
Comprehensive Income Net Of Tax -
Ebit -$64M
Ebitda -$53M
Net Income -$71M

ADAP News

ADAP Profile

Adaptimmune Therapeutics Plc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company headquartered in Abingdon, UK, dedicated to developing innovative T-cell therapies targeting solid tumors. With a focus on harnessing the power of the immune system, Adaptimmune leverages its proprietary SPEAR T-cell platform to design personalized therapies aimed at improving patient outcomes. The company operates primarily within the United States and the United Kingdom, positioning itself at the forefront of immuno-oncology advancements. As it progresses through key clinical trials, Adaptimmune is committed to addressing the significant unmet medical needs of cancer patients through its cutting-edge therapeutic solutions.

DVLT
+24.58%
$1.04
INTC
+8.87%
$33.99
GPUS
+18.64%
$0.45
CGBS
-39.47%
$0.03
DFLI
+34.88%
$0.51
SNAP
-0.78%
$8.26
YAAS
-31.07%
$0.06
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.39%
$12.01
PSTV
+9.60%
$0.61
DNN
-3.32%
$2.76
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-6.02%
$7.02
ADAP
+15.74%
$0.14
NEHC
+49.83%
$1.38
NUAI
+49.83%
$1.38
WOK
-5.22%
$0.08
GUTS
+32.67%
$1.34
AAL
-0.62%
$11.31
PLTR
-0.24%
$179.12
RIG
+0.79%
$3.18
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
IONZ
+6.93%
$4.39
BBD
-2.09%
$3.27
MRM
+117.24%
$3.15
QBTS
+1.55%
$26.75
VALE
-1.74%
$10.70
BTG
+1.54%
$4.92
IREN
-9.57%
$41.86
BLMZ
+11.89%
$0.19
QUBT
-2.11%
$20.14
LYT
-16.77%
$0.09
MARA
+0.37%
$16.13
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
RXRX
-5.12%
$4.63
AAPL
-0.54%
$255.46
ATCH
-4.22%
$0.79
FCX
+1.14%
$35.74
AMZN
+0.74%
$219.78
TLRY
-3.21%
$1.15
RMBL
+60.50%
$3.21
BITF
-4.84%
$2.55
SOUN
-2.45%
$15.94
IXHL
-0.01%
$0.59
KVUE
+0.34%
$16.22
ADD
-25.47%
$0.05
SHOT
+11.96%
$0.27
RIVN
-0.95%
$15.59
ETHD
-6.03%
$3.94
ONDS
-1.16%
$7.66
RR
+2.68%
$4.20
CLSK
-5.26%
$12.96
RAYA
-5.04%
$0.04
SRM
+53.27%
$10.30
BMNR
+1.73%
$50.43
ACHR
-0.48%
$9.28
BURU
-8.76%
$0.12
HOOD
-3.27%
$122.65
BULL
+2.35%
$14.98
IONQ
-3.07%
$67.29
GRAB
-2.67%
$6.08
NOK
-0.53%
$4.65
SOFI
-0.51%
$27.97
CVE
-0.02%
$17.69
AMD
-1.12%
$159.46
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BB
+6.45%
$4.95
WBD
-0.82%
$19.61
CRWV
-4.98%
$120.34
PFE
+0.63%
$23.75
WLGS
-5.57%
$0.04
JOBY
+2.03%
$16.18
HIMS
+6.39%
$58.38
ABEV
+0.21%
$2.30
QS
+2.20%
$12.77
AG
+2.27%
$11.67
AQMS
+48.37%
$7.30
ETWO
0.00%
$3.30
AIIO
-15.63%
$2.04
SDM
-86.40%
$1.85
BTE
+2.06%
$2.51
CLF
+2.34%
$12.35
ITUB
+0.62%
$7.24
OKLO
-7.40%
$110.31
MU
+0.28%
$157.27
AFMD
-34.94%
$0.18
MRVL
-0.45%
$83.43
WAI
+48.10%
$4.68
HBAN
+0.72%
$17.44
CAN
+0.20%
$0.79
ORCL
-2.61%
$283.69
DVLT
+24.58%
$1.04
INTC
+8.87%
$33.99
GPUS
+18.64%
$0.45
CGBS
-39.47%
$0.03
DFLI
+34.88%
$0.51
SNAP
-0.78%
$8.26
YAAS
-31.07%
$0.06
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.39%
$12.01
PSTV
+9.60%
$0.61
DNN
-3.32%
$2.76
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-6.02%
$7.02
ADAP
+15.74%
$0.14
NEHC
+49.83%
$1.38
NUAI
+49.83%
$1.38
WOK
-5.22%
$0.08
GUTS
+32.67%
$1.34
AAL
-0.62%
$11.31
PLTR
-0.24%
$179.12
RIG
+0.79%
$3.18
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
IONZ
+6.93%
$4.39
BBD
-2.09%
$3.27
MRM
+117.24%
$3.15
QBTS
+1.55%
$26.75
VALE
-1.74%
$10.70
BTG
+1.54%
$4.92
IREN
-9.57%
$41.86
BLMZ
+11.89%
$0.19
QUBT
-2.11%
$20.14
LYT
-16.77%
$0.09
MARA
+0.37%
$16.13
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
RXRX
-5.12%
$4.63
AAPL
-0.54%
$255.46
ATCH
-4.22%
$0.79
FCX
+1.14%
$35.74
AMZN
+0.74%
$219.78
TLRY
-3.21%
$1.15
RMBL
+60.50%
$3.21
BITF
-4.84%
$2.55
SOUN
-2.45%
$15.94
IXHL
-0.01%
$0.59
KVUE
+0.34%
$16.22
ADD
-25.47%
$0.05
SHOT
+11.96%
$0.27
RIVN
-0.95%
$15.59
ETHD
-6.03%
$3.94
ONDS
-1.16%
$7.66
RR
+2.68%
$4.20
CLSK
-5.26%
$12.96
RAYA
-5.04%
$0.04
SRM
+53.27%
$10.30
BMNR
+1.73%
$50.43
ACHR
-0.48%
$9.28
BURU
-8.76%
$0.12
HOOD
-3.27%
$122.65
BULL
+2.35%
$14.98
IONQ
-3.07%
$67.29
GRAB
-2.67%
$6.08
NOK
-0.53%
$4.65
SOFI
-0.51%
$27.97
CVE
-0.02%
$17.69
AMD
-1.12%
$159.46
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BB
+6.45%
$4.95
WBD
-0.82%
$19.61
CRWV
-4.98%
$120.34
PFE
+0.63%
$23.75
WLGS
-5.57%
$0.04
JOBY
+2.03%
$16.18
HIMS
+6.39%
$58.38
ABEV
+0.21%
$2.30
QS
+2.20%
$12.77
AG
+2.27%
$11.67
AQMS
+48.37%
$7.30
ETWO
0.00%
$3.30
AIIO
-15.63%
$2.04
SDM
-86.40%
$1.85
BTE
+2.06%
$2.51
CLF
+2.34%
$12.35
ITUB
+0.62%
$7.24
OKLO
-7.40%
$110.31
MU
+0.28%
$157.27
AFMD
-34.94%
$0.18
MRVL
-0.45%
$83.43
WAI
+48.10%
$4.68
HBAN
+0.72%
$17.44
CAN
+0.20%
$0.79
ORCL
-2.61%
$283.69
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.